{"title":"Age-disproportionate atrophy in Alzheimer's disease and Parkinson's disease spectra.","authors":"Kenji Yoshinaga, Toma Matsushima, Mitsunari Abe, Tsunehiko Takamura, Hiroki Togo, Noritaka Wakasugi, Nobukatsu Sawamoto, Toshiya Murai, Toshiki Mizuno, Teruyuki Matsuoka, Kazuaki Kanai, Hiroshi Hoshino, Atsushi Sekiguchi, Nobuo Fuse, Shunji Mugikura, Takashi Hanakawa","doi":"10.1002/dad2.70048","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Brain age gap (BAG), defined as the difference between MRI-predicted 'brain age' and chronological age, can capture information underlying various neurological disorders. We investigated the pathophysiological significance of the BAG across neurodegenerative disorders.</p><p><strong>Methods: </strong>We developed a brain age estimator using structural MRIs of healthy-aged individuals from one cohort study. Subsequently, we applied this estimator to people with Alzheimer's disease spectra (AD) and Parkinson's disease (PD) from another cohort study. We investigated brain sources responsible for BAGs among these groups.</p><p><strong>Results: </strong>Both AD and PD exhibited a positive BAG. Brain sources showed overlapping, yet partially segregated, neuromorphological differences between these groups. Furthermore, employing with t-distributed stochastic neighbor embedding on the brain sources, we subclassified PD into two groups with and without cognitive impairment.</p><p><strong>Discussion: </strong>Our findings suggest that brain age estimation becomes a clinically relevant method for finely stratifying neurodegenerative disorders.</p><p><strong>Highlights: </strong>Brain age estimated from structure MRI data was greater than chronological age in patients with Alzheimer's disease/mild cognitive impairment or Parkinson's disease.Brain regions attributed to brain age estimation were located mainly in the fronto-temporo-parietal cortices but not in the motor cortex or subcortical regions.Brain sources responsible for the brain age gaps revealed roughly overlapping, yet partially segregated, neuromorphological differences between participants with Alzheimer's disease/mild cognitive impairment and Parkinson's disease.Participants with Parkinson's disease were subclassified into two groups (with and without cognitive impairment) based on brain sources responsible for the brain age gaps.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 1","pages":"e70048"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780112/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Brain age gap (BAG), defined as the difference between MRI-predicted 'brain age' and chronological age, can capture information underlying various neurological disorders. We investigated the pathophysiological significance of the BAG across neurodegenerative disorders.
Methods: We developed a brain age estimator using structural MRIs of healthy-aged individuals from one cohort study. Subsequently, we applied this estimator to people with Alzheimer's disease spectra (AD) and Parkinson's disease (PD) from another cohort study. We investigated brain sources responsible for BAGs among these groups.
Results: Both AD and PD exhibited a positive BAG. Brain sources showed overlapping, yet partially segregated, neuromorphological differences between these groups. Furthermore, employing with t-distributed stochastic neighbor embedding on the brain sources, we subclassified PD into two groups with and without cognitive impairment.
Discussion: Our findings suggest that brain age estimation becomes a clinically relevant method for finely stratifying neurodegenerative disorders.
Highlights: Brain age estimated from structure MRI data was greater than chronological age in patients with Alzheimer's disease/mild cognitive impairment or Parkinson's disease.Brain regions attributed to brain age estimation were located mainly in the fronto-temporo-parietal cortices but not in the motor cortex or subcortical regions.Brain sources responsible for the brain age gaps revealed roughly overlapping, yet partially segregated, neuromorphological differences between participants with Alzheimer's disease/mild cognitive impairment and Parkinson's disease.Participants with Parkinson's disease were subclassified into two groups (with and without cognitive impairment) based on brain sources responsible for the brain age gaps.
期刊介绍:
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.